Europeans consider citalopram dosing after FDA action and Canadian review
This article was originally published in Scrip
Executive Summary
The UK medicines regulator is working with other European regulatory authorities to decide whether to restrict the maximum daily dose of the antidepressant citalopram following action taken in North America in light of heart safety data.
You may also be interested in...
Gaming Whiz Brings AI Smarts To Drug Discovery
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
The Top 10 Best-Selling Drugs of 2019
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Interview: Why Biotech Companies Should Be Confident About Deals Despite Coronavirus
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
Need a specific report? 1000+ reports available
Buy Reports